Active	Status	Sponsor type	Region	Phase	Filter
5 Active 4 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kalunian, Kenneth
SELUNE, NCT04181762 / 2019-003211-57: Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis	Terminated	3	275	Europe, Canada, Japan, US, RoW	secukinumab, AIN457, Placebo	Novartis Pharmaceuticals	Lupus Nephritis	09/23	09/23
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis	Recruiting	3	420	Europe, Canada, US, RoW	ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Lupus Nephritis	03/27	07/30
EQUALISE, NCT04128579: Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis Apr 2022 - Sep 2022 : Interim data from Type B portion of EQUALISE trial for SLE with lupus nephritis Safety data from EQUALISE trial for SLE Aug 2021 - Aug 2021: Safety data from EQUALISE trial for SLE Additional data from type A portion of EQUALISE trial for SLE Aug 2021 - Aug 2021: Additional data from type A portion of EQUALISE trial for SLE Topline data from type A cohort of EQUALISE trial for SLE Mar 2021 - Mar 2021: Topline data from type A cohort of EQUALISE trial for SLE Data from type A cohorts (1–4) from EQUALISE trial for SLE Nov 2020 - Nov 2020: Data from type A cohorts (1–4) from EQUALISE trial for SLE More	Completed	1	55	Europe, US, RoW	Itolizumab [Bmab 600], Bmab600, Itolizumab	Equillium, Biocon Limited	Lupus Erythematosus, Lupus Nephritis	11/23	01/24